2022
Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useAssociation of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer
Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC, Boffa DJ. Association of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer. JAMA Network Open 2022, 5: e2217581. PMID: 35713907, PMCID: PMC9206181, DOI: 10.1001/jamanetworkopen.2022.17581.Peer-Reviewed Original ResearchAssociation Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristics
2021
Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States
Salazar MC, Kaminski MF, Canavan ME, Maduka RC, Li AX, Ermer T, Boffa DJ. Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States. JAMA Oncology 2021, 7: 1394-1395. PMID: 34292299, PMCID: PMC8299357, DOI: 10.1001/jamaoncol.2021.2582.Peer-Reviewed Original ResearchThe Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical And Research Reports 2021, 2: 100143. PMID: 34590002, PMCID: PMC8474228, DOI: 10.1016/j.jtocrr.2021.100143.Peer-Reviewed Original ResearchStage I NSCLCWedge resectionSurveillance EpidemiologyMortality riskHigh riskSurvival advantageLife expectancyNational Cancer Institute's Surveillance EpidemiologyEnd Results-MedicareTreatment-naive patientsEarly-stage NSCLCRetrospective cohort studySuperior local controlShort life expectancyLife expectancy decreasesPerioperative complicationsCohort studyComorbid conditionsLung parenchymaLobectomyCox modelReasonable optionPatientsNSCLCLocal control
2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncology 2020, 6: 1741-1750. PMID: 32940636, PMCID: PMC7499246, DOI: 10.1001/jamaoncol.2020.4232.Peer-Reviewed Original ResearchConceptsNode-negative non-small cell lung cancerHigh-risk pathologic featuresNon-small cell lung cancerAdjuvant chemotherapyCell lung cancerPathologic featuresTumor sizeSurvival benefitCohort studyLung cancerNode-negative NSCLCEarly-stage non-small cell lung cancerCox proportional hazards regression modelHigh-risk clinicopathologic featuresProportional hazards regression modelsNational Cancer DatabaseRetrospective cohort studyTreatment-naive patientsAdjuvant chemotherapy useHigh-risk featuresAssociation of survivalHazards regression modelsImmortal time biasChemotherapy useEligible patients